Nasal cavity and paranasal sinus lethal midline granuloma

Summary

Nasal cavity and paranasal sinus lethal midline granuloma (MONDO:0006828) is a disease. A subtype of nasal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity and paranasal sinus lethal midline granuloma
Mondo ID	MONDO:0006828
EFO	EFO:1001013
MeSH	D006103
DOID	DOID:9072
NCIT	C8196
UMLS	C0018197
MedGen	42292
MedDRA	10024255
Is cancer (heuristic)	no

Also known as: midfacial Necrotising lesion · Midline lethal granuloma of nasal cavity and paranasal sinus · Midline lethal granuloma of the nasal cavity and paranasal sinus · nasal cavity and paranasal sinus lethal Midline granuloma

Disease family

This is a subtype of nasal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › nasal cavity and paranasal sinus lethal midline granuloma

Related subtypes (4): paranasal sinus disorder, nasal cavity disorder, anosmia, nasal dermoid cyst

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 10 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Alemtuzumab	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)
Oxaliplatin	Phase 3 (in late-stage trials)
Pegaspargase	Phase 3 (in late-stage trials)
Sugemalimab	Phase 3 (in late-stage trials)
Thalidomide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Basiliximab, Bevacizumab, Camrelizumab, Cisplatin, Decitabine, Fludarabine Phosphate, Melphalan, Mycophenolate Mofetil, Pembrolizumab, Sintilimab, Tacrolimus Anhydrous, Tislelizumab, Tofacitinib, Toripalimab, Tucidinostat.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.